

Introduction to the Cholera Vaccine Work Group

Pablo Sanchez, MD

Chair, Cholera Vaccine Work Group

Advisory Committee on Immunization Practices

October 28, 2020



Cholera vaccine work group members

ACIP members

- Pablo Sanchez (chair)
- Jose Romero (interim)

Ex officio members

- Robert Hall (NIH)
- Tina Mongeau (FDA)

CDC lead

- Jenn Collins

Liason representatives

- Carol Baker (IDSA)
- Elizabeth Barnett (ISTM)
- Adam Ratner (AAP)

Consultants

- Matt Daley (Kaiser Permanente)
- Ed Ryan (Harvard)
- Mary Wilson (Harvard/UCSF)

CDC contributors

- Grace Appiah
- Bruce Gutelius
- Eric Mintz
- Talia Pindyk
- John Su
- Farrell Tobolowsky

Background and purpose of the work group

- In 2017, ACIP recommended the cholera vaccine CVD 103-HgR for adult travelers (aged 18–64 years) from the United States to an area of active cholera transmission.
- This workgroup will review more recent pediatric data to inform whether ACIP should recommend cholera vaccine for travelers aged 2–17 years.

Policy topic under consideration by work group

- Should ACIP cholera vaccine recommendations be expanded to include children and adolescents aged 2–17 years?

Work group activities

- Review available safety and immunogenicity data for CVD 103-HgR among children and adolescents.
- Develop evidence-based recommendations using the GRADE approach.
- Update MMWR.

Thank you!

Questions?

